TScan Therapeutics (NASDAQ:TCRX) Cut to Hold at Lifesci Capital

TScan Therapeutics (NASDAQ:TCRX) was downgraded by equities research analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks reports.

A number of other equities research analysts also recently weighed in on TCRX. Wedbush downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research report on Wednesday. HC Wainwright reiterated a “buy” rating on shares of TScan Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday, July 17th. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a report on Thursday, August 13th. Finally, Wall Street Zen cut TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.67.

TScan Therapeutics Trading Down 2.7%

Shares of NASDAQ:TCRX opened at $0.37 on Wednesday. The company has a 50 day moving average of $0.84 and a 200-day moving average of $0.98. The firm has a market cap of $25.14 million, a P/E ratio of -0.41 and a beta of 1.07. TScan Therapeutics has a twelve month low of $0.35 and a twelve month high of $2.57. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.31.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. As a group, analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Panagora Asset Management Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter valued at $25,000. Landscape Capital Management L.L.C. acquired a new stake in shares of TScan Therapeutics during the second quarter worth $25,000. HRT Financial LP purchased a new stake in shares of TScan Therapeutics during the fourth quarter valued at $26,000. Public Employees Retirement System of Ohio purchased a new stake in shares of TScan Therapeutics during the first quarter valued at $28,000. Finally, Boothbay Fund Management LLC boosted its position in shares of TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.